P1.04-50 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

Pembrolizumab has demonstrated its usefulness as a primary treatment for metastatic non-small cell lung cancer (NSCLC) in Keynote-024 and Keynote-042. However, there is little information on the usefulness of pembrolizumab in clinical practice. The purpose of this study is to examine whether the efficacy reported in Keynote-024 and Keynote-042 is reproduced in real world setting. This study is retrospective multicenter trial. From Feb 2017 to...